Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting

PR Newswire December 1, 2021

Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer

PR Newswire November 30, 2021

Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca(TM) (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade

PR Newswire November 30, 2021

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

PR Newswire November 9, 2021

Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance

PR Newswire November 9, 2021

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting

PR Newswire November 4, 2021

Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021

PR Newswire October 26, 2021

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

PR Newswire September 13, 2021

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

PR Newswire September 8, 2021

Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

PR Newswire August 31, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

PR Newswire August 12, 2021

Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers

PR Newswire August 10, 2021

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

PR Newswire August 10, 2021

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results

PR Newswire August 3, 2021

National Comprehensive Cancer Network® Adds Newly Approved Rylaze(TM) (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

PR Newswire July 22, 2021

Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021

PR Newswire July 20, 2021

Jazz Pharmaceuticals Announces Rylaze(TM) (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021

PR Newswire July 13, 2021

Health Canada Approves Vyxeos®, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML)

PR Newswire July 7, 2021

Horizons ETFs Rebalances Marijuana-Focused Index Etfs

PR Newswire July 6, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze(TM) (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

PR Newswire June 30, 2021